Join Growin Stock Community!

Adaptive biotechnologies corporationADPT.US Overview

US StockHealthcare
(No presentation for ADPT)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

ADPT AI Insights

ADPT Overall Performance

ADPT AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

ADPT Recent Performance

-1.78%

Adaptive biotechnologies corporation

0.05%

Avg of Sector

-0.31%

S&P500

ADPT PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

ADPT Key Information

ADPT Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

ADPT Profile

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunoSEQ, a platform and core immunosequencing product that is used to answer translational research questions, as well as to discover new prognostic and diagnostic signals; and T-Detect COVID for the confirmation of past COVID-19 infection. It also provides clonoSEQ, a clinical diagnostic product for the detection and monitoring of minimal residual disease in patients with multiple myeloma, B cell acute lymphoblastic leukemia, and chronic lymphocytic leukemia, as well as available as a CLIA-validated laboratory developed test for patients with other lymphoid cancers; and immunoSEQ T-MAP COVID for vaccine developers and researchers to measure the T-cell immune response to vaccines. In addition, the company offers a pipeline of clinical products and services that are used for the diagnosing, monitoring, and treatment of diseases, such as cancer, autoimmune conditions, and infectious diseases. It serves the life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.

Price of ADPT

ADPT FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

ADPT Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-0.39
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
8.89
PB Ratio
11.27
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
74.24%
Net Margin
-21.48%
Revenue Growth (YoY)
54.77%
Profit Growth (YoY)
92.39%
3-Year Revenue Growth
9.10%
3-Year Profit Growth
11.46%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-0.39
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
8.89
PB Ratio
11.27
Price-to-FCF
-
Gross Margin
74.24%
Net Margin
-21.48%
Revenue Growth (YoY)
54.77%
Profit Growth (YoY)
92.39%
3-Year Revenue Growth
9.10%
3-Year Profit Growth
11.46%

  • When is ADPT's latest earnings report released?

    The most recent financial report for Adaptive biotechnologies corporation (ADPT) covers the period of 2025Q4 and was published on 2025/12/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating ADPT's short-term business performance and financial health. For the latest updates on ADPT's earnings releases, visit this page regularly.

  • What is the operating profit of ADPT?

    According to the latest financial report, Adaptive biotechnologies corporation (ADPT) reported an Operating Profit of -12.77M with an Operating Margin of -17.82% this period, representing a growth of 62.25% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.

  • How is ADPT's revenue growth?

    In the latest financial report, Adaptive biotechnologies corporation (ADPT) announced revenue of 71.68M, with a Year-Over-Year growth rate of 51.04%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much debt does ADPT have?

    As of the end of the reporting period, Adaptive biotechnologies corporation (ADPT) had total debt of 210.36M, with a debt ratio of 0.41. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does ADPT have?

    At the end of the period, Adaptive biotechnologies corporation (ADPT) held Total Cash and Cash Equivalents of 73.18M, accounting for 0.14 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does ADPT go with three margins increasing?

    In the latest report, Adaptive biotechnologies corporation (ADPT) did not achieve the “three margins increasing” benchmark, with a gross margin of 74.6%%, operating margin of -17.82%%, and net margin of -18.9%%. This demonstrates limited improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess ADPT's profit trajectory and future growth potential.

  • Is ADPT's EPS continuing to grow?

    According to the past four quarterly reports, Adaptive biotechnologies corporation (ADPT)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at -0.09. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of ADPT?

    Adaptive biotechnologies corporation (ADPT)'s Free Cash Flow (FCF) for the period is 1.42M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 111.29% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.

  • What are the PEG ratio and PE ratio of ADPT?

    The latest valuation data shows Adaptive biotechnologies corporation (ADPT) has a Price-To-Earnings (PE) ratio of -42.6 and a Price/Earnings-To-Growth (PEG) ratio of 0.19. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.